0001209191-21-068113.txt : 20211206
0001209191-21-068113.hdr.sgml : 20211206
20211206164714
ACCESSION NUMBER: 0001209191-21-068113
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211123
FILED AS OF DATE: 20211206
DATE AS OF CHANGE: 20211206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zinda Michael
CENTRAL INDEX KEY: 0001815366
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39335
FILM NUMBER: 211473640
MAIL ADDRESS:
STREET 1: C/O REPARE THERAPEUTICS INC.
STREET 2: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Repare Therapeutics Inc.
CENTRAL INDEX KEY: 0001808158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
BUSINESS PHONE: (857) 412-7018
MAIL ADDRESS:
STREET 1: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-23
0
0001808158
Repare Therapeutics Inc.
RPTX
0001815366
Zinda Michael
C/O REPARE THERAPEUTICS INC.
7210 FREDERICK-BANTING, SUITE 100
ST-LAURENT
A8
H4S 2A1
QUEBEC, CANADA
0
1
0
0
EVP, Chief Science Officer
Common Shares
2021-11-23
4
M
0
4122
1.637
A
4655
D
Common Shares
2021-11-23
4
M
0
11856
1.637
A
16511
D
Common Shares
2021-11-23
4
M
0
19590
2.062
A
36101
D
Common Shares
2021-11-23
4
M
0
10473
2.425
A
46574
D
Employee Stock Option (right to buy)
1.637
2021-11-23
4
M
0
4122
0.00
D
2027-06-14
Common Shares
4122
0
D
Employee Stock Option (right to buy)
1.637
2021-11-23
4
M
0
11856
0.00
D
2027-12-04
Common Shares
11856
0
D
Employee Stock Option (right to buy)
2.062
2021-11-23
4
M
0
19590
0.00
D
2029-03-29
Common Shares
19590
35260
D
Employee Stock Option (right to buy)
2.425
2021-11-23
4
M
0
10473
0.00
D
2029-12-16
Common Shares
10473
137993
D
Fully vested and exercisable.
Twenty-five percent (25%) of the shares subject to the option vested on March 29, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Twenty-five percent (25%) of the shares subject to the option vested on December 16, 2020, and one thirty-ninth (1/39th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
/s/ Steve Forte, Attorney-in-Fact
2021-12-06